This quarter is a seasonally strong Q for disc sales with an expected increase in rotor sales over last Q of 15% (based on prior years), and a poor Q for instrument sales.

One should not therefore view Jonathan Block's caution about Piccolo sales as a voice of doom, and I would expect that ABAX will come in with $0.18 - could be wrong of course! They do have extra consumables to sell.

Q3 is the time for instrument sales and I look forward to the CC on prospects and UCC trials - keep the pipe filled and sales will happen, but it all takes time, and doctors are always more difficult than VETS.

JB is the star analyst for ABAX and his comments are well made, but you have to look back at sales of the VETSCAN in the early days to understand the amount of Sceptism in the market, before the ball started to roll.

Hang in there and we should be back to $40 again